Your browser doesn't support javascript.
loading
Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients.
Moura, David S; Ramos, Rafael; Fernandez-Serra, Antonio; Serrano, Teresa; Cruz, Julia; Alvarez-Alegret, Ramiro; Ortiz-Duran, Rosa; Vicioso, Luis; Gomez-Dorronsoro, Maria Luisa; Garcia Del Muro, Xavier; Martinez-Trufero, Javier; Rubio-Casadevall, Jordi; Sevilla, Isabel; Lainez, Nuria; Gutierrez, Antonio; Serrano, Cesar; Lopez-Alvarez, Maria; Hindi, Nadia; Taron, Miguel; López-Guerrero, José Antonio; Martin-Broto, Javier.
Afiliação
  • Moura DS; Institute of Biomedicine of Sevilla (IBiS, HUVR, CSIC, University of Sevilla), Sevilla, Spain.
  • Ramos R; Pathology Department, Son Espases University Hospital, Palma, Illes Baleares, Spain.
  • Fernandez-Serra A; Laboratory of Molecular Biology, Valencian Oncologic Institute, Valencia, Spain.
  • Serrano T; Pathology Department, Bellvitge University Hospital, IDIBELL, Barcelona, Spain.
  • Cruz J; Pathology Department, Valencian Oncologic Institute, Valencia, Spain.
  • Alvarez-Alegret R; Pathology Department, Miguel Servet University Hospital, Zaragoza, Spain.
  • Ortiz-Duran R; Pathology Department, Josep Trueta University Hospital, Girona, Spain.
  • Vicioso L; Pathology Department, Virgen de la Victoria University Hospital, Malaga, Spain.
  • Gomez-Dorronsoro ML; Pathology Department, Hospital Complex of Navarra, Pamplona, Spain.
  • Garcia Del Muro X; Medical Oncology Department, Institut Català d'Oncologia, IDIBELL, Universitat de Barcelona, Barcelona, Spain.
  • Martinez-Trufero J; Medical Oncology Department, Miguel Servet University Hospital, Zaragoza, Spain.
  • Rubio-Casadevall J; Medical Oncology Department, Catalan Oncologic Institute, Josep Trueta University Hospital, Girona, Spain.
  • Sevilla I; Medical Oncology Department, Virgen de la Victoria University Hospital, Malaga, Spain.
  • Lainez N; Medical Oncology Department, Hospital Complex of Navarra, Pamplona, Spain.
  • Gutierrez A; Hematology Department, Son Espases University Hospital, Palma, Illes Baleares, Spain.
  • Serrano C; Medical Oncology Department, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Lopez-Alvarez M; Institute of Biomedicine of Sevilla (IBiS, HUVR, CSIC, University of Sevilla), Sevilla, Spain.
  • Hindi N; Institute of Biomedicine of Sevilla (IBiS, HUVR, CSIC, University of Sevilla), Sevilla, Spain.
  • Taron M; Medical Oncology Department, University Hospital Virgen del Rocio, Sevilla, Spain.
  • López-Guerrero JA; Institute of Biomedicine of Sevilla (IBiS, HUVR, CSIC, University of Sevilla), Sevilla, Spain.
  • Martin-Broto J; Laboratory of Molecular Biology, Valencian Oncologic Institute, Valencia, Spain.
Oncotarget ; 9(25): 17576-17588, 2018 Apr 03.
Article em En | MEDLINE | ID: mdl-29707131
INTRODUCTION: There are limited findings available on KIT-negative GIST-like (KNGL) population. Also, KIT expression may be post-transcriptionally regulated by miRNA221 and miRNA222. Hence, the aim of this study is to characterize KNGL population, by differential gene expression, and to analyze miRNA221/222 expression and their prognostic value in KNGL patients. METHODS: KIT, PDGFRA, DOG1, IGF1R, MIR221 and MIR222 expression levels were determined by qRT-PCR. We also analyzed KIT and PDGFRA mutations, DOG1 expression, by immunohistochemistry, along with clinical and pathological data. Disease-free survival (DFS) and overall survival (OS) differences were calculated using Log-rank test. RESULTS: Hierarchical cluster analyses from gene expression data identified two groups: group I had KIT, DOG1 and PDGFRA overexpression and IGF1R underexpression and group II had overexpression of IGF1R and low expression of KIT, DOG1 and PDGFRA. Group II had a significant worse OS (p = 0.013) in all the series, and showed a tendency for worse OS (p = 0.11), when analyzed only the localized cases. MiRNA222 expression was significantly lower in a control subset of KIT-positive GIST (p < 0.001). OS was significantly worse in KNGL cases with higher expression of MIR221 (p = 0.028) or MIR222 (p = 0.014). CONCLUSIONS: We identified two distinct KNGL subsets, with a different prognostic value. Increased levels of miRNA221/222, which are associated with worse OS, could explain the absence of KIT protein expression of most KNGL tumors.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Oncotarget Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Oncotarget Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Espanha